InflaRx N.V. (NASDAQ: IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...

Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...

InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

SPOKANE, Wash. — A family is pleading for help to save the life of Ryan Becker, who is fighting an extremely rare and devastating illness known as Pyoderma Gangrenosum, a condition described by ...

SPOKANE, Wash. — A Spokane father is facing a devastating choice between financial ruin and his life as he battles an extremely rare disease that requires tens of thousands in monthly medication to ...

A 63-year-old woman with a 20-year history of hidradenitis suppurativa, classified as Hurley Stage III (a disease-specific staging system); a 12 pack-year smoking history; pyoderma gangrenosum; and ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

Watch Out for This Skin Infection That Can Be Caused by Your Dog's Allergies originally appeared on PetHelpful. Q: "Charlie has this rash on his stomach area and is obsessed with licking it. He’s a ...

InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to the drawing board. The independent data monitoring committee assessing a ...